Oxford Bioscience

Oxford BioTherapeutics (OBT) is a clinical-stage oncology company dedicated to the discovery and development of first-in-class antibody-based therapies for the treatment of cancer. The company leverages its proprietary OGAP-Verify platform, one of the world's largest proteomic databases, to identify novel membrane protein targets that are overexpressed in solid and hematological tumors. OBT's pipeline includes a diverse range of modalities, such as antibody-drug conjugates (ADCs), immuno-oncology (IO) agents, and T-cell engagers. Its lead clinical program, OBT076, is an ADC targeting CD205 currently being evaluated in Phase 1/2 trials for advanced solid tumors. OBT has established high-profile strategic collaborations with global pharmaceutical leaders, including Roche and GSK, to accelerate the development of its novel oncology targets.